MNP for Vaccines

Technical Development

According to the market report (Greystone, 2016), MNP has great potential to develop a large market, particularly for vaccines. WCC is cooperating with the National Health Research Institute (NHRI),the objective is to combine the advanced B5 type vaccine developed by NHRI for Endovirus 71 type with the MNP by WCC. NHRI has organized an “Asian Endovirus Detection League”, which includes 8 countries such as vietnam, Malaysia and so on. The new borns in these countries can benefit from the MNP Vaccines in the future.


Application

Endovirus MNP EV71 type vaccine/Others
Advantages
1. The amount of vaccine can be substantially reduced to less than 20 %.
2. Painless application is highly acceptable.
3. N
o need to go to hospitals.
4. MNP is in solid form, no need for low-temperature storage, transportation is much cheaper (cold chain not required).

Cooperation
RD or others.